Chardan Healthcare Acquisition 2 Corp. does not have significant operations. It intends to acquire assets and businesses through a merger, share exchange, stock purchase, recapitalization, reorganization, or other similar business combination. The company was incorporated in 2018 and is based in New York, New York.
IPO Year: 2020
Exchange: AMEX
Website: chardanhealthcarespac.com
| Date | Price Target | Rating | Analyst |
|---|
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Renovacor, Inc. (0001799850) (Issuer)
3 - Renovacor, Inc. (0001799850) (Issuer)
4 - Renovacor, Inc. (0001799850) (Issuer)
4 - Renovacor, Inc. (0001799850) (Issuer)
4 - Renovacor, Inc. (0001799850) (Issuer)
4 - Renovacor, Inc. (0001799850) (Issuer)
S-1 - Renovacor, Inc. (0001799850) (Filer)
8-K - Renovacor, Inc. (0001799850) (Filer)
8-K - Renovacor, Inc. (0001799850) (Filer)
25-NSE - Chardan Healthcare Acquisition 2 Corp. (0001799850) (Subject)
8-K - Chardan Healthcare Acquisition 2 Corp. (0001799850) (Filer)
DEFA14A - Chardan Healthcare Acquisition 2 Corp. (0001799850) (Filer)
DEFA14A - Chardan Healthcare Acquisition 2 Corp. (0001799850) (Filer)
DEFA14A - Chardan Healthcare Acquisition 2 Corp. (0001799850) (Filer)
DEFA14A - Chardan Healthcare Acquisition 2 Corp. (0001799850) (Filer)
DEFM14A - Chardan Healthcare Acquisition 2 Corp. (0001799850) (Filer)
Fastest customizable press release news feed in the world
Common stock and warrants of the combined company, renamed Renovacor, Inc., will commence trading on September 3, 2021 on the NYSE under ticker symbols "RCOR" and "RCOR.WS", respectively. Gross proceeds from the transaction totaled approximately $95.1 million. Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the closing of its previously announced business combination with Chardan Healthcare Acquisition 2 Corp. (NYSE:CHAQ) ("CHAQ"), a special purpose acquisition company sponsored by Chardan Cap
NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (NYSE:CHAQ) ("CHAQ"), a special purpose acquisition company sponsored by Chardan Capital Markets ("Chardan"), today announced the results for the proposals considered and voted upon by its stockholders at its special meeting held on September 1, 2021 (the "Special Meeting"), regarding the proposed business combination with Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants. CHAQ reported that all of the various proposals giving effect to
NEW YORK, Aug. 25, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor"), an early–stage biotechnology company developing adeno-associated virus (AAV)–based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Matt Killeen, Ph.D., as chief scientific officer (CSO), effective as of September 1, 2021. Chardan Healthcare Acquisition 2 Corp. (CHAQ) previously announced on March 23, 2021 that it entered into a definitive merger agreement with Renovacor, Inc. The closing of the merger is expected to occur in the third quarter of 2021. "Matt's extensive experience discovering, researching and developing
PHILADELPHIA and NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (the "Company") announced that the close of business on Thursday, August 5, 2021, has been set as the record date for the determination of stockholders eligible to receive the proxy and vote at the special meeting to be held to consider and approve the previously announced merger with Renovacor, Inc., a Delaware corporation ("Renovacor"). On March 23, 2021, Renovacor and the Company announced a definitive agreement for a business combination that would result in Renovacor becoming a publicly listed company. A proxy statement, once final, will be mailed together with a proxy card to the Company's
PHILADELPHIA, July 19, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Elizabeth (Beth) White, Ph.D., as chief business officer and senior vice president of operations. "Beth is a proven industry professional who possesses a unique blend of business, scientific and drug strategy experience from leadership roles in global pharma and biotech companies that will guide the development of our lead candidate, REN-001," said Magdalene Cook, M.D., chief exec
PHILADELPHIA, July 12, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jiwen Zhang, Ph.D., as senior vice president, regulatory affairs and quality assurance. "Jiwen's extensive regulatory expertise and experience advancing AAV-based gene therapies into the clinic will be invaluable assets for Renovacor," said Magdalene Cook, M.D., chief executive officer of Renovacor. "She has successfully built regulatory affairs functions at companies of varying s
PHILADELPHIA and BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system ("CNS") diseases resulting from BAG3 gene variants, today announced the appointment of Marc Semigran, M.D., as chief medical officer of Renovacor. Dr. Semigran brings considerable clinical development and translational medicine experience to Renovacor, having previously served as chief medical officer and senior vice president of medical science at MyoKardia through its acquisition by Bristol Myers Squibb ("BMS") in 2020 for $13.1 billion. He will
PHILADELPHIA and NEW YORK, March 23, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor" or the "Company"), an early-stage biotechnology company developing AAV-based gene therapies for devastating cardiovascular and central nervous system (CNS) diseases resulting from BAG3 gene dysfunction, and Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purpose acquisition company or SPAC, sponsored by affiliates of Chardan Capital Markets ("Chardan"), announced today they have entered into a definitive business combination agreement. Upon closing of the transaction, CHAQ will be renamed Renovacor, Inc. and its common stock is expected to be listed on NYSE under the ticker symbol "
Live Leadership Updates
NEW YORK, Aug. 25, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor"), an early–stage biotechnology company developing adeno-associated virus (AAV)–based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Matt Killeen, Ph.D., as chief scientific officer (CSO), effective as of September 1, 2021. Chardan Healthcare Acquisition 2 Corp. (CHAQ) previously announced on March 23, 2021 that it entered into a definitive merger agreement with Renovacor, Inc. The closing of the merger is expected to occur in the third quarter of 2021. "Matt's extensive experience discovering, researching and developing
PHILADELPHIA, July 19, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Elizabeth (Beth) White, Ph.D., as chief business officer and senior vice president of operations. "Beth is a proven industry professional who possesses a unique blend of business, scientific and drug strategy experience from leadership roles in global pharma and biotech companies that will guide the development of our lead candidate, REN-001," said Magdalene Cook, M.D., chief exec
PHILADELPHIA, July 12, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jiwen Zhang, Ph.D., as senior vice president, regulatory affairs and quality assurance. "Jiwen's extensive regulatory expertise and experience advancing AAV-based gene therapies into the clinic will be invaluable assets for Renovacor," said Magdalene Cook, M.D., chief executive officer of Renovacor. "She has successfully built regulatory affairs functions at companies of varying s
PHILADELPHIA and BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system ("CNS") diseases resulting from BAG3 gene variants, today announced the appointment of Marc Semigran, M.D., as chief medical officer of Renovacor. Dr. Semigran brings considerable clinical development and translational medicine experience to Renovacor, having previously served as chief medical officer and senior vice president of medical science at MyoKardia through its acquisition by Bristol Myers Squibb ("BMS") in 2020 for $13.1 billion. He will
This live feed shows all institutional transactions in real time.
SC 13D - Renovacor, Inc. (0001799850) (Subject)
SC 13G/A - Renovacor, Inc. (0001799850) (Subject)
SC 13G - Chardan Healthcare Acquisition 2 Corp. (0001799850) (Subject)
SC 13G - Chardan Healthcare Acquisition 2 Corp. (0001799850) (Subject)
SC 13G - Chardan Healthcare Acquisition 2 Corp. (0001799850) (Subject)